Rallybio Corp Dossier
Qualitative Analysis
Business overview
Rallybio Corp (NASDAQ: RLYB) is a clinical-stage biotechnology company historically focused on identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, primarily in maternal-fetal health, complement-mediated disorders, and hematology. The company's lead legacy programs include RLYB212, a monoclonal antibody designed to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT), and RLYB116, a subcutaneous inhibitor of complement component C5. However, following development and financing challenges, Rallybio entered into a definitive merger agreement on June 1, 2026, to acquire private oncology-focused biotech Avenzo Therapeutics, Inc. in a reverse merger transaction. Upon closing, the combined company will operate under the name Avenzo Therapeutics, Inc., trade under the ticker symbol 'AVZO', and pivot its core business focus to next-generation oncology therapies, including selective CDK inhibitors and antibody-drug conjugates (ADCs).
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Rallybio entered into a definitive merger agreement to acquire Avenzo Therapeutics, Inc., transforming the combined entity into a publicly traded oncology-focused biotechnology company.
Expected impact: Shifts operational focus to Avenzo's oncology pipeline (selective CDK inhibitors and bispecific ADCs) and funds operations into late 2028.
Rallybio exited its small-molecule development partnership with Recursion Pharmaceuticals for the sale of its interest in REV102, an investigational ENPP1 inhibitor.
Expected impact: Generated $20 million in total proceeds ($7.5 million upfront and $12.5 million related to preclinical studies) to extend cash runway.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To acquire Avenzo's next-generation oncology pipeline, including selective CDK inhibitors and bispecific antibody-drug conjugates, and transition the combined company's focus to oncology under the Avenzo name.
Financial impact: Pre-transaction Rallybio equityholders will own approximately 2.8% of the combined company, which will be backed by a concurrent $215 million private placement funding operations into late 2028.
Strategic Partnerships
High
Terms: Rallybio entered into a collaboration agreement in the second quarter of 2024, receiving over $7 million to access Rallybio's natural history study for fetal and neonatal alloimmune thrombocytopenia (FNAIT).